ClinicalTrials.gg
CompletedNCT03818256GRATITUDEUpdated Sep 19, 2024Results posted

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

A Phase 2 interventional study of Miricorilant and Placebo in Antipsychotic-induced Weight Gain (AIWG), sponsored by Corcept Therapeutics. Completed at 27 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with antipsychotic medications.

Read the detailed description

This is a randomized, double-blind, placebo-controlled study that will assess the safety, efficacy, and PK of miricorilant in obese patients with schizophrenia or bipolar disorder who are currently taking oral or injectable atypical antipsychotic medication.

Patients who meet the criteria for the Study CORT118335-876 will be randomized on Day 1 to receive 600 mg miricorilant or placebo for 12 weeks.

02

Conditions studied

  • Antipsychotic-induced Weight Gain (AIWG)

Keywords

  • Antipsychotic-induced weight gain (AIWG)
  • Obesity
  • Weight Gain
  • Mental disorders
  • Schizophrenia
  • Risperidone
  • Quetiapine
  • Olanzapine
  • Bipolar Disorder
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 71 is close to the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of schizophrenia or bipolar disorder
  • Are currently taking oral or injectable atypical antipsychotic medication (except clozapine) and must have documented weight gain while on these medications
  • Must be on a stable dose of medication for 1 month prior to Screening
  • Are able to successfully complete placebo tablet swallow test
  • Have a ≥30 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • Have a history of a medical condition affecting body weight (eg, poorly controlled hyper- or hypothyroidism; eating disorder such as anorexia, bulimia, or binge eating; or polycystic ovary syndrome)
  • Have poorly controlled diabetes mellitus
  • Have poorly controlled hypertension
  • Have a history of symptomatic hypotension
  • Have a history of orthostatic hypotension.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Miricorilant 600 mg

    Patients who meet the entry criteria will be randomized to receive 600 mg miricorilant for 12 weeks.

    Drug: Miricorilant

  • Placebo comparator
    Placebo

    Patients who meet the entry criteria will be randomized to receive placebo for 12 weeks.

    Drug: Placebo

Interventions

  • Miricorilant 600 mg (6 X 100 mg tablets) for once-daily oral dosing

    Also known as: CORT118335

  • DrugPlacebo

    Placebo tablets for once-daily oral dosing

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Body Weight at Week 12 for 600 mg Miricorilant Versus Placebo

    Time frame: Baseline Day 1 and Week 12

  2. Number of Patients With One or More Treatment-emergent Adverse Events

    Time frame: Up to Follow-up Visit (Week 16)

  3. Number of Patients With One or More Treatment-emergent Serious Adverse Events

    Time frame: Up to Follow-up Visit (up to Week 16)

  4. Number of Patients With One or More Treatment-emergent Adverse Events Leading to Early Study Discontinuation

    Time frame: Up to Follow-up Visit (up to Week 16)

Secondary outcomes

  1. Percentage of Patients Achieving More Than or Equal to 5% Weight Loss

    Time frame: Baseline Day 1 to Week 12

  2. Change From Baseline in HOMA-IR at Week 12

    HOMA-IR = \[fasting plasma glucose (mg/dL) X fasting insulin (µU/mL)\]/405. HOMA-IR is a method to evaluate insulin sensitivity. The HOMA-IR score should be ≤1.0 to be considered normal. A score \>1.9 indicates early insulin resistance and a score \>2.9 indicates significant insulin resistance.

    Time frame: Baseline Day 1 and Week 12

  3. Change From Baseline in Waist-to-hip Ratio at Week 12

    Waist-to-hip ratio compares the circumference of the waist to the circumference of the hips. The ratio is calculated by dividing the waist measurement by the hip measurement, using the same units of measurement for both. A waist-to-hip ratio \<0.95 in men and \<0.80 in women is considered healthy.

    Time frame: Baseline Day 1 and Week 12

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneMiricorilant 600 mgPlacebo
Started3536
Completed2728
Not completed88
Withdrew: Withdrawal by subject22
Withdrew: Adverse event31
Withdrew: Lost to follow-up05
Withdrew: Gaining weight without prohibited medication vyvanse10
Withdrew: Not reporting for scheduled visits10
Withdrew: Non-compliant with investigational product10

Outcome measures

PrimaryChange From Baseline in Body Weight at Week 12 for 600 mg Miricorilant Versus Placebo
Time frame:
Baseline Day 1 and Week 12
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight at Week 12 for 600 mg Miricorilant Versus Placebo
kgMiricorilant 600 mgPlacebo
Change From Baseline in Body Weight at Week 12 for 600 mg Miricorilant Versus Placebo-0.98 ± 0.414-1.08 ± 0.415
Statistical analysis
  • Miricorilant 600 mg vs Placebo · Mixed Models Analysis · p = 0.8511 · Least squares mean difference: 0.11 · 95% CI -1.03 to 1.24
PrimaryNumber of Patients With One or More Treatment-emergent Adverse Events
Time frame:
Up to Follow-up Visit (Week 16)
Reported as:
Count of participants · Participants
Number of Patients With One or More Treatment-emergent Adverse Events
ParticipantsMiricorilant 600 mgPlacebo
Number of Patients With One or More Treatment-emergent Adverse Events1618
PrimaryNumber of Patients With One or More Treatment-emergent Serious Adverse Events
Time frame:
Up to Follow-up Visit (up to Week 16)
Reported as:
Count of participants · Participants
Number of Patients With One or More Treatment-emergent Serious Adverse Events
ParticipantsMiricorilant 600 mgPlacebo
Number of Patients With One or More Treatment-emergent Serious Adverse Events11
PrimaryNumber of Patients With One or More Treatment-emergent Adverse Events Leading to Early Study Discontinuation
Time frame:
Up to Follow-up Visit (up to Week 16)
Reported as:
Count of participants · Participants
Number of Patients With One or More Treatment-emergent Adverse Events Leading to Early Study Discontinuation
ParticipantsMiricorilant 600 mgPlacebo
Number of Patients With One or More Treatment-emergent Adverse Events Leading to Early Study Discontinuation31
SecondaryPercentage of Patients Achieving More Than or Equal to 5% Weight Loss
Time frame:
Baseline Day 1 to Week 12
Reported as:
Count of participants · Participants
Percentage of Patients Achieving More Than or Equal to 5% Weight Loss
ParticipantsMiricorilant 600 mgPlacebo
Percentage of Patients Achieving More Than or Equal to 5% Weight Loss23
Statistical analysis
  • Miricorilant 600 mg vs Placebo · Regression, Logistic · p = 0.8169 · Odds ratio (or): 0.82 · 95% CI 0.150 to 4.474
SecondaryChange From Baseline in HOMA-IR at Week 12

HOMA-IR = \[fasting plasma glucose (mg/dL) X fasting insulin (µU/mL)\]/405. HOMA-IR is a method to evaluate insulin sensitivity. The HOMA-IR score should be ≤1.0 to be considered normal. A score \>1.9 indicates early insulin resistance and a score \>2.9 indicates significant insulin resistance.

Time frame:
Baseline Day 1 and Week 12
Reported as:
Median · HOMA-IR score
Change From Baseline in HOMA-IR at Week 12
HOMA-IR scoreMiricorilant 600 mgPlacebo
Change From Baseline in HOMA-IR at Week 121.080 (-2.020 to 3.780)0.890 (-0.970 to 2.400)
Statistical analysis
  • Miricorilant 600 mg vs Placebo · Wilcoxon rank-sum test · p = 0.9285 · Location shift: 0.175 · 95% CI -2.860 to 2.780
SecondaryChange From Baseline in Waist-to-hip Ratio at Week 12

Waist-to-hip ratio compares the circumference of the waist to the circumference of the hips. The ratio is calculated by dividing the waist measurement by the hip measurement, using the same units of measurement for both. A waist-to-hip ratio \<0.95 in men and \<0.80 in women is considered healthy.

Time frame:
Baseline Day 1 and Week 12
Reported as:
Least squares mean · Ratio
Change From Baseline in Waist-to-hip Ratio at Week 12
RatioMiricorilant 600 mgPlacebo
Change From Baseline in Waist-to-hip Ratio at Week 120.008 ± 0.00920.001 ± 0.0091
Statistical analysis
  • Miricorilant 600 mg vs Placebo · Mixed Models Analysis · p = 0.5669 · Least squares mean difference: 0.007 · 95% CI -0.018 to 0.033

Adverse events

Collected over Baseline Day 1 to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Miricorilant 600 mg0/35 (0%)1/35 (2.9%)12/35 (34.3%)
Placebo0/36 (0%)1/36 (2.8%)5/36 (13.9%)
Most frequent serious events
Most frequent serious events
EventMiricorilant 600 mgPlacebo
Hyperthermia malignantGeneral disorders1/350/36
Toxicity to various agentsInjury, poisoning and procedural complications1/350/36
ManiaPsychiatric disorders0/351/36
Most frequent other events
Most frequent other events
EventMiricorilant 600 mgPlacebo
DiarrhoeaGastrointestinal disorders5/350/36
Alanine aminotransferase increasedInvestigations4/352/36
NauseaGastrointestinal disorders3/350/36
Aspartate aminotransferase increasedInvestigations3/351/36
AkathisiaNervous system disorders2/350/36
Orthostatic hypotensionVascular disorders2/350/36
AnaemiaBlood and lymphatic system disorders0/352/36
SomnolenceNervous system disorders0/352/36

Baseline characteristics

All enrolled patients

Age, Continuous
Age, Continuous(Years)Miricorilant 600 mgPlaceboTotal
Mean43.9 ± 10.5047.5 ± 11.7845.7 ± 11.24
Sex: Female, Male
Sex: Female, Male(Participants)Miricorilant 600 mgPlaceboTotal
Female192039
Male161632
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Miricorilant 600 mgPlaceboTotal
Hispanic or Latino7916
Not Hispanic or Latino282755
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Miricorilant 600 mgPlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American131629
White212041
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Miricorilant 600 mgPlaceboTotal
United States353671
Body weight
Body weight(kg)Miricorilant 600 mgPlaceboTotal
Mean110.39 ± 20.01107.69 ± 25.41109.02 ± 22.79
Homeostatic model assessment for insulin resistance (HOMA-IR)
Homeostatic model assessment for insulin resistance (HOMA-IR)(HOMA-IR score)Miricorilant 600 mgPlaceboTotal
Mean8.687 ± 5.718.463 ± 17.278.577 ± 13.24
Waist-to-hip ratio
Waist-to-hip ratio(Ratio)Miricorilant 600 mgPlaceboTotal
Mean1.032 ± 0.240.967 ± 0.100.999 ± 0.18
08

Study locations

27 sites
  • Site 143
    Bentonville, Arkansas 72712, United States
  • Site 249
    Little Rock, Arkansas 72211, United States
  • Site 153
    Culver City, California 90230, United States
  • Site 239
    Garden Grove, California 92845, United States
  • Site 134
    Lemon Grove, California 91945, United States
  • Site 126
    Oakland, California 94607, United States
  • Site 163
    Oceanside, California 92056, United States
  • Site 229
    Rancho Cucamonga, California 91730, United States
  • Site 202
    Miami, Florida 33122, United States
  • Site 144
    North Miami, Florida 33161, United States
  • Site 241
    Okeechobee, Florida 34972, United States
  • Site 140
    Chicago, Illinois 60641, United States
  • Site 140
    Lincolnwood, Illinois 60712, United States
  • Site 146
    Wichita, Kansas 67214, United States
  • Site 138
    Glen Burnie, Maryland 20161, United States
  • Site 151
    Las Vegas, Nevada 89102, United States
  • Site 216
    New York, New York 10032, United States
  • Site 181
    Raleigh, North Carolina 27608, United States
  • Site 181
    Raleigh, North Carolina 27610, United States
  • Site 107
    Dayton, Ohio 45417, United States
  • Site 235
    Thorndale, Pennsylvania 19372, United States
  • Site 235
    West Chester, Pennsylvania 19380, United States
  • Site 206
    DeSoto, Texas 75115, United States
  • Site 066
    Houston, Texas 77030, United States
  • Site 165
    Richardson, Texas 75080, United States
  • Site 139
    Salt Lake City, Utah 84105, United States
  • Site 137
    Bellevue, Washington 98007, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jun 2022, 30 months.

Results were first posted in Sep 2024, 2 years 3 months after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 30 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2019
First posted
Jan 28, 2019
StartActual
Dec 4, 2019
Primary completionActual
Jun 17, 2022
CompletionActual
Jul 6, 2022
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03818256
Responsible party
Sponsor
First posted
Jan 28, 2019
Start date
Dec 4, 2019
Primary completion
Jun 17, 2022
Completion
Jul 6, 2022
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Kavita Juneja, MD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT118335

Start the discussion